Last reviewed · How we verify
Sulphadoxine-pyrimethamine and Amodiaquine
Sulphadoxine-pyrimethamine and Amodiaquine is a Small molecule drug developed by London School of Hygiene and Tropical Medicine. It is currently in Phase 1 development. Also known as: SPAQ.
At a glance
| Generic name | Sulphadoxine-pyrimethamine and Amodiaquine |
|---|---|
| Also known as | SPAQ |
| Sponsor | London School of Hygiene and Tropical Medicine |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Perennial Malaria Chemoprevention in the Malaria Vaccine Era (PHASE4)
- Preventing Malaria in School Children to Protect the Whole Community in Rural Blantyre District, Malawi (PHASE4)
- Parasite Clearance and Protection from Infection (PCPI) in Cameroon (PHASE3)
- Efficacy and Safety of Sulphadoxine-pyrimethamine and Amodiaquine in Ghanaian Pregnant Women (PHASE3)
- Evaluation of Vector and Chemoprevention-based Interventions to Reduce Malaria Burden in Urban Daaras of Touba, Senegal (PHASE4)
- Seasonal Malaria Vaccination (RTS,S/AS01) and Seasonal Malaria Chemoprevention (SP/AQ) Extension Study (PHASE3)
- Enhancing Preventive Therapy of Malaria In Children With Sickle Cell Anemia in East Africa (EPiTOMISE) (PHASE4)
- Seasonal Malaria Chemoprevention Rapid Assessment Study Mozambique (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sulphadoxine-pyrimethamine and Amodiaquine CI brief — competitive landscape report
- Sulphadoxine-pyrimethamine and Amodiaquine updates RSS · CI watch RSS
- London School of Hygiene and Tropical Medicine portfolio CI
Frequently asked questions about Sulphadoxine-pyrimethamine and Amodiaquine
What is Sulphadoxine-pyrimethamine and Amodiaquine?
Sulphadoxine-pyrimethamine and Amodiaquine is a Small molecule drug developed by London School of Hygiene and Tropical Medicine.
Who makes Sulphadoxine-pyrimethamine and Amodiaquine?
Sulphadoxine-pyrimethamine and Amodiaquine is developed by London School of Hygiene and Tropical Medicine (see full London School of Hygiene and Tropical Medicine pipeline at /company/london-school-of-hygiene-and-tropical-medicine).
Is Sulphadoxine-pyrimethamine and Amodiaquine also known as anything else?
Sulphadoxine-pyrimethamine and Amodiaquine is also known as SPAQ.
What development phase is Sulphadoxine-pyrimethamine and Amodiaquine in?
Sulphadoxine-pyrimethamine and Amodiaquine is in Phase 1.
Related
- Manufacturer: London School of Hygiene and Tropical Medicine — full pipeline
- Also known as: SPAQ